Gibson Dunn and Goodwin Procter has advised Dianthus Therapeutics, Inc., while Cooley has represented the underwriters. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on antibody...
Dianthus Therapeutics Closes $288 Million Public Offering of Common Stock and Pre-Funded Warrants
Dianthus Therapeutics’ $230 Million Private Placement
Gibson, Dunn & Crutcher LLP represented Dianthus Therapeutics, Inc. on the placement. Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...